Physician profile
Emile Wassel
NPI 1023047552
$8,751.39
in general payments reported to CMS, 2019-2025
41 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $475 · 2021: $750 · 2022: $1,216 · 2023: $2,287 · 2024: $1,833 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,610 · Education: $118 · Consulting Fee: $22.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,610.11 |
| Education | $118.20 |
| Consulting Fee | $22.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,180.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,110.20 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Amgen INC. | $707.62 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Otsuka America Pharmaceutical, INC. | $489.29 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $480.14 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $450.43 | 2022-2025 | Tarpeyo |
| Harmony Biosciences LLC | $439.89 | 2023-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $383.70 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.79 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $316.37 | 2021-2025 | |
| Vifor Pharma, INC. | $270.35 | 2019-2023 | Veltassa |
| Alnylam Pharmaceuticals INC. | $269.32 | 2021-2024 | Givlaari |
| Mallinckrodt Hospital Products INC. | $260.37 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $205.39 | 2019-2023 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $204.93 | 2019-2024 | Velphoro |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $156.36 | 2019 | |
| Philips North America LLC | $145.20 | 2019-2023 | |
| Travere Therapeutics, INC. | $144.53 | 2023-2025 | |
| Grifols USA, LLC | $134.65 | 2021-2025 | Prolastin-C Liquid |
| Lilly USA, LLC | $125.15 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $110.37 | 2024-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $101.61 | 2024-2025 | Ibsrela |
| Daiichi Sankyo INC. | $98.67 | 2020-2021 | |
| Akebia Therapeutics INC | $90.05 | 2019-2025 | Vafseo |
| Baxter Healthcare | $66.58 | 2022-2024 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $59.56 | 2019-2021 | |
| Mylan Specialty L.P. | $51.00 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $46.62 | 2024 | Lupkynis |
| Scpharmaceuticals INC. | $44.06 | 2025 | |
| Electromed, INC. | $42.03 | 2024 | Smartvest |
| Novo Nordisk INC | $37.70 | 2023-2024 | Rivfloza, Ozempic, Rybelsus |
| Pfizer INC. | $36.37 | 2023-2024 | |
| Ars Pharmaceuticals Operations, INC. | $23.74 | 2025 | Neffy |
| Shield Therapeutics INC | $23.30 | 2023 | Accrufer |
| Boston Scientific Corporation | $22.90 | 2023 | Watchman Access System |
| Alexion Pharmaceuticals, INC. | $19.94 | 2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2023 | Glassia |
| Merck Sharp & Dohme LLC | $15.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.52 | 2023 | Xifaxan, Trulance |
| Bard Peripheral Vascular, INC. | $13.77 | 2020 | |
| Rockwell Medical, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emile Wassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.